Unfunded in New Zealand: Why Pharmac Says No, and What It Costs Patients

New Zealanders keep discovering the same painful fact at the worst possible moment: a medicine can be approved, effective and routinely funded in Australia or the UK, and still cost tens of thousands of dollars out of pocket in New Zealand. The reason is not that the medicine is unproven. It is that New Zealand runs medicine funding through a single agency with a fixed budget, and the queue at that budget is long. Here is how the system actually works and what the honest options are when your medicine is not on the list.

In short

• Pharmac decides which medicines are publicly funded in New Zealand, from a fixed annual budget, and its choices bind the whole public system.
• Around 300 funding applications are waiting, some for years, including medicines standard elsewhere.
• Budget 2026 gave Pharmac an uplift of under 1 percent, described by health economists as barely keeping the lights on.
• Unfunded means you can still be prescribed it, but you pay: privately purchased, via insurance that covers non-Pharmac medicines, or not at all.
• The model has a real upside, some of the world's lowest prices for what is funded, and a real downside, slow access to what is not.

How does Pharmac decide what gets funded?

Pharmac ranks funding applications against each other and pays for as many as its fixed budget allows, so a medicine can be assessed as beneficial and still wait indefinitely. The agency negotiates hard on price, which is why New Zealand pays less for funded medicines than almost any comparable country, as Pharmac itself explains. The flip side is structural: when the budget is spent, everything else waits, however good the evidence. That is how roughly 300 applications, including modern cancer drugs and treatments standard across the Tasman, can sit in the queue while patients crowdfund.

What does "unfunded" mean for me in practice?

Your doctor can prescribe an unfunded medicine, but the public system will not pay for it, so the cost lands on you or your insurer. For some medicines that is a manageable monthly sum; for modern oncology drugs it can be tens of thousands of dollars a year, the situation the Breast Cancer Foundation NZ documents for women paying privately for treatments Pharmac funds only at a later disease stage. Private health insurance increasingly sells non-Pharmac medicine cover precisely for this gap, and it is worth checking whether a policy includes it before you need it, because you cannot add it after diagnosis.

Why not just fund everything effective?

Because the fixed-budget model is a deliberate trade: maximum price leverage and predictable spending, at the cost of rationing by queue. Every health system rations somewhere; New Zealand's version is unusually visible. Defenders point to the prices Pharmac extracts and the discipline of comparing medicines against each other. Critics point to years-long waits for treatments with strong evidence, and to Budget 2026's uplift, less than one percent of Pharmac's budget, as proof the model is underfed rather than merely disciplined. Both things can be true, and the practical consequence for patients is the same either way: the list is the list, and what is off it costs you.

What are the honest options if my medicine is unfunded?

Five, roughly in order of usefulness.

• Check the funded alternatives seriously. Often a funded medicine in the same class does most of the job; the generic versions of established medicines are exactly where Pharmac's model shines, and why a generic is the same medicine is worth understanding before paying brand prices anywhere.
• Ask about Named Patient / exceptional-circumstances routes. Pharmac runs mechanisms for individual funding in defined situations; they are narrow but real.
• Private insurance with non-Pharmac cover, if you hold it already, is the designed answer for the big-ticket gap.
• Paying privately at a pharmacy is legitimate and sometimes cheaper than assumed for older medicines; for newer ones, ask the prescriber whether a clinical trial or access program exists.
• Advocacy, through patient groups, genuinely moves the list over time; several recent fundings followed sustained public campaigns.

One current example of the gap: weight-loss medicines such as semaglutide for obesity are not publicly funded, so New Zealanders using them pay privately, a situation mirrored in several countries covered in our GLP-1 cost guides.

The bottom line

Pharmac is neither villain nor miracle: it is a fixed budget doing exactly what fixed budgets do, buying funded medicines cheaply and making everything else wait. If your medicine is unfunded, the useful moves are checking funded alternatives, exploring the exception routes, and knowing the private costs honestly rather than assuming the system will catch you. Rules and lists change, so check Pharmac's current schedule for anything that matters to you.

This article is educational and does not replace advice from a doctor or pharmacist who knows your health history.